COMP <GO>
EVMN vs ELDN // DIVIDEND YIELD & FCF PAYOUT SAFETY
Evommune Inc. (NYSE) VS. Eledon Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: EVMN 2
— ELDN 1
■ METRIC PARITY
LAST: $6.81 (+7.92%) • MKT CAP: $247.1M
dividend-safety
0.00%
LAST: $3.04 (+10.15%) • MKT CAP: $247.0M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EVMN VS. ELDN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EVMN | ELDN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 85.70% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.87 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | EVMN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.5 | 58.0 | -8.52 | ELDN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $247.1M | $247.0M | $115.4K | EVMN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EVMN REV | ELDN REV | EVMN GROSS % | ELDN GROSS % | EVMN FCF | ELDN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $13.0M | $0 | — | — | -$76.7M | -$62.3M |
| FY 2024 | $7.0M | $0 | — | — | -$58.3M | -$47.3M |
| FY 2023 | — | $0 | — | — | — | -$39.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EVMN // BETA —
ELDN // BETA —